JP2016506914A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506914A5 JP2016506914A5 JP2015553175A JP2015553175A JP2016506914A5 JP 2016506914 A5 JP2016506914 A5 JP 2016506914A5 JP 2015553175 A JP2015553175 A JP 2015553175A JP 2015553175 A JP2015553175 A JP 2015553175A JP 2016506914 A5 JP2016506914 A5 JP 2016506914A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- acid sequence
- amino acid
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2013/001480 WO2014111744A1 (en) | 2013-01-16 | 2013-01-16 | A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019149672A Division JP2020015733A (ja) | 2019-08-19 | 2019-08-19 | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016506914A JP2016506914A (ja) | 2016-03-07 |
| JP2016506914A5 true JP2016506914A5 (enExample) | 2016-11-17 |
Family
ID=48289519
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015553175A Withdrawn JP2016506914A (ja) | 2013-01-16 | 2013-01-16 | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド |
| JP2015553074A Withdrawn JP2016506912A (ja) | 2013-01-16 | 2014-01-16 | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド |
| JP2019021752A Expired - Fee Related JP6995069B2 (ja) | 2013-01-16 | 2019-02-08 | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015553074A Withdrawn JP2016506912A (ja) | 2013-01-16 | 2014-01-16 | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド |
| JP2019021752A Expired - Fee Related JP6995069B2 (ja) | 2013-01-16 | 2019-02-08 | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US20150344855A1 (enExample) |
| EP (2) | EP2945967B1 (enExample) |
| JP (3) | JP2016506914A (enExample) |
| KR (3) | KR20160002681A (enExample) |
| CN (1) | CN105121464B (enExample) |
| AU (2) | AU2013373679A1 (enExample) |
| CA (2) | CA2898415A1 (enExample) |
| DK (1) | DK2945967T3 (enExample) |
| EA (2) | EA201591324A1 (enExample) |
| ES (1) | ES2796743T3 (enExample) |
| HU (1) | HUE049556T2 (enExample) |
| IL (2) | IL239810A0 (enExample) |
| MX (2) | MX372787B (enExample) |
| PE (1) | PE20151664A1 (enExample) |
| PL (1) | PL2945967T3 (enExample) |
| PT (1) | PT2945967T (enExample) |
| SG (2) | SG11201505488XA (enExample) |
| SI (1) | SI2945967T1 (enExample) |
| WO (2) | WO2014111744A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013373679A1 (en) | 2013-01-16 | 2015-08-13 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | A soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders |
| PT3242888T (pt) * | 2015-01-07 | 2020-12-28 | Pfizer | Armadilhas de fgfr3 solúveis para o tratamento de distúrbios do crescimento ósseo |
| KR101981774B1 (ko) * | 2016-04-25 | 2019-05-27 | 장부다 | Vr 공간에서 사용자 인터페이스를 제공하는 방법, 디바이스 및 기록매체 |
| HUE058734T2 (hu) * | 2016-07-07 | 2022-09-28 | Pfizer | Szolúbilis 3-as fibroblaszt növekedési faktor receptor (sFGFR3) polipeptidek és alkalmazásaik |
| BR112020005459A2 (pt) * | 2017-09-20 | 2020-09-29 | Pfizer Inc. | tratamento de deposição de gordura visceral anormal usando polipeptídeos de receptor 3 de fator de crescimento de fibroblasto solúvel (sfgfr3) |
| CN108410803B (zh) * | 2018-03-28 | 2019-02-05 | 湖南源品细胞生物科技有限公司 | 一种诱导脂肪干细胞成软骨分化的培养方法和培养液 |
| CN110272900B (zh) * | 2019-04-19 | 2024-03-26 | 中国人民解放军陆军军医大学 | 用于制备骨骼发育异常猪模型的sgRNA及其应用 |
| WO2022106976A1 (en) | 2020-11-18 | 2022-05-27 | Pfizer Inc. | Stable pharmaceutical formulations of soluble fgfr3 decoys |
| WO2022254319A1 (en) | 2021-06-01 | 2022-12-08 | Pfizer Inc. | Cell culture method for producing sfgfr3 polypeptide |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308236D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Dna vectors |
| IL122473A (en) | 1995-06-12 | 2003-11-23 | Yeda Res & Dev | Fgfr3 as a marker for mesenchymal skeletal progenitor cells |
| US7067144B2 (en) | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
| US7598055B2 (en) | 2000-06-28 | 2009-10-06 | Glycofi, Inc. | N-acetylglucosaminyltransferase III expression in lower eukaryotes |
| US7625756B2 (en) | 2000-06-28 | 2009-12-01 | GycoFi, Inc. | Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells |
| US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
| ATE440959T1 (de) | 2000-06-28 | 2009-09-15 | Glycofi Inc | Verfahren für die herstellung modifizierter glykoproteine |
| US7863020B2 (en) | 2000-06-28 | 2011-01-04 | Glycofi, Inc. | Production of sialylated N-glycans in lower eukaryotes |
| US20040109850A1 (en) * | 2000-12-18 | 2004-06-10 | Neelam Jaiswal | Treatment of bone disorders by modulation of fgfr3 |
| IL142118A0 (en) | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
| CA2450793A1 (en) | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| JP4252746B2 (ja) * | 2001-10-05 | 2009-04-08 | 一和 中尾 | 軟骨無形成症治療剤 |
| BRPI0203172B8 (pt) * | 2001-09-28 | 2021-05-25 | Nakao Kazuwa | composição farmacêutica para acondroplasia |
| JP2003104908A (ja) * | 2001-09-28 | 2003-04-09 | Ichikazu Nakao | 軟骨無形成症治療剤 |
| US7332299B2 (en) | 2003-02-20 | 2008-02-19 | Glycofi, Inc. | Endomannosidases in the modification of glycoproteins in eukaryotes |
| IL156495A0 (en) * | 2003-06-17 | 2004-01-04 | Prochon Biotech Ltd | Use of fgfr3 antagonists for treating t cell mediated diseases |
| DK1718756T3 (da) | 2004-02-24 | 2012-02-27 | Allergan Inc | Botulinumtoksinscreeningassays |
| ES2336832T3 (es) * | 2005-07-22 | 2010-04-16 | Five Prime Therapeutics, Inc. | Composiciones y procedimientos para tratar enfermedades con proteinas de fusion de fgfr. |
| WO2007144893A2 (en) | 2006-06-15 | 2007-12-21 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
| WO2008038287A2 (en) | 2006-09-28 | 2008-04-03 | Hepacore Ltd. | N-terminal fgf variants having increased receptor selectivity and uses thereof |
| AR063975A1 (es) | 2006-11-28 | 2009-03-04 | Centelion | Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada |
| WO2008133873A2 (en) * | 2007-04-25 | 2008-11-06 | Aveo Pharmaceuticals, Inc. | Fgf-binding fusion proteins |
| US8426396B2 (en) | 2008-01-08 | 2013-04-23 | Shriners Hospitals For Children | Treatment for achondroplasia |
| US8187601B2 (en) | 2008-07-01 | 2012-05-29 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (FGFR3) binding proteins |
| CN102171343B (zh) | 2008-08-04 | 2017-07-14 | 戊瑞治疗有限公司 | Fgfr细胞外结构域酸性区突变蛋白 |
| AR073770A1 (es) | 2008-10-20 | 2010-12-01 | Imclone Llc | Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden |
| HRP20150965T1 (hr) | 2009-03-25 | 2015-11-06 | Genentech, Inc. | Anti-fgr3 protutijela i metode koje ih koriste |
| CN101585866B (zh) * | 2009-07-02 | 2011-10-05 | 中国人民解放军第三军医大学野战外科研究所 | 调节fgfr3活性的多肽及其筛选方法和应用 |
| EP2478003A4 (en) | 2009-09-15 | 2013-05-29 | Five Prime Therapeutics Inc | HAIR GROWING PROCEDURES USING EXTRACELLULAR FGFR4 DOMAINS |
| CA2780457A1 (en) | 2009-11-13 | 2011-05-19 | Five Prime Therapeutics, Inc. | Use of fgfr1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in fgfr2 |
| EP2512501A4 (en) | 2009-12-17 | 2014-01-01 | Five Prime Therapeutics Inc | METHODS FOR PROMOTING HAIR GROWTH USING FGFR3 EXTRACELLULAR DOMAINS |
| US20120328599A1 (en) | 2010-01-14 | 2012-12-27 | Yale University | Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| EP2658979B1 (en) * | 2010-12-27 | 2018-02-14 | Alexion Pharmaceuticals, Inc. | Compositions comprising natriuretic peptides and methods of use thereof |
| CN102219860B (zh) | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | FGFR-Fc融合蛋白及其用途 |
| AU2012328880B2 (en) | 2011-10-24 | 2017-02-23 | Halozyme, Inc. | Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof |
| FR2984325A1 (fr) | 2011-12-14 | 2013-06-21 | Sanofi Sa | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
| ES2932954T5 (en) | 2012-07-24 | 2025-10-28 | Univ Columbia | Fgfr-tacc fusion proteins and methods thereof |
| US20140030259A1 (en) | 2012-07-27 | 2014-01-30 | Genentech, Inc. | Methods of treating fgfr3 related conditions |
| WO2014071419A2 (en) | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
| AU2013373679A1 (en) | 2013-01-16 | 2015-08-13 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | A soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders |
| PL3097122T3 (pl) | 2014-01-24 | 2020-10-19 | Ngm Biopharmaceuticals, Inc. | Przeciwciała wiążące domenę 2 beta klotho oraz sposoby ich stosowania |
| PT3242888T (pt) | 2015-01-07 | 2020-12-28 | Pfizer | Armadilhas de fgfr3 solúveis para o tratamento de distúrbios do crescimento ósseo |
| HUE058734T2 (hu) | 2016-07-07 | 2022-09-28 | Pfizer | Szolúbilis 3-as fibroblaszt növekedési faktor receptor (sFGFR3) polipeptidek és alkalmazásaik |
| BR112020005459A2 (pt) | 2017-09-20 | 2020-09-29 | Pfizer Inc. | tratamento de deposição de gordura visceral anormal usando polipeptídeos de receptor 3 de fator de crescimento de fibroblasto solúvel (sfgfr3) |
-
2013
- 2013-01-16 AU AU2013373679A patent/AU2013373679A1/en not_active Abandoned
- 2013-01-16 CA CA2898415A patent/CA2898415A1/en not_active Abandoned
- 2013-01-16 WO PCT/IB2013/001480 patent/WO2014111744A1/en not_active Ceased
- 2013-01-16 SG SG11201505488XA patent/SG11201505488XA/en unknown
- 2013-01-16 JP JP2015553175A patent/JP2016506914A/ja not_active Withdrawn
- 2013-01-16 KR KR1020157022203A patent/KR20160002681A/ko not_active Withdrawn
- 2013-01-16 EA EA201591324A patent/EA201591324A1/ru unknown
- 2013-01-16 US US14/759,490 patent/US20150344855A1/en not_active Abandoned
-
2014
- 2014-01-16 HU HUE14702206A patent/HUE049556T2/hu unknown
- 2014-01-16 EP EP14702206.5A patent/EP2945967B1/en active Active
- 2014-01-16 AU AU2014206844A patent/AU2014206844A1/en not_active Abandoned
- 2014-01-16 KR KR1020217013228A patent/KR20210054026A/ko not_active Withdrawn
- 2014-01-16 PL PL14702206T patent/PL2945967T3/pl unknown
- 2014-01-16 SG SG11201505140XA patent/SG11201505140XA/en unknown
- 2014-01-16 EP EP20167861.2A patent/EP3736285A1/en not_active Withdrawn
- 2014-01-16 PT PT147022065T patent/PT2945967T/pt unknown
- 2014-01-16 US US14/759,535 patent/US10724014B2/en not_active Expired - Fee Related
- 2014-01-16 PE PE2015001353A patent/PE20151664A1/es not_active Application Discontinuation
- 2014-01-16 ES ES14702206T patent/ES2796743T3/es active Active
- 2014-01-16 JP JP2015553074A patent/JP2016506912A/ja not_active Withdrawn
- 2014-01-16 CA CA2896978A patent/CA2896978A1/en active Pending
- 2014-01-16 EA EA201591055A patent/EA201591055A1/ru unknown
- 2014-01-16 KR KR1020157022078A patent/KR102249454B1/ko not_active Expired - Fee Related
- 2014-01-16 CN CN201480005077.6A patent/CN105121464B/zh not_active Expired - Fee Related
- 2014-01-16 WO PCT/EP2014/050800 patent/WO2014111467A1/en not_active Ceased
- 2014-01-16 SI SI201431607T patent/SI2945967T1/sl unknown
- 2014-01-16 MX MX2015009142A patent/MX372787B/es active IP Right Grant
- 2014-01-16 DK DK14702206.5T patent/DK2945967T3/da active
-
2015
- 2015-07-06 IL IL239810A patent/IL239810A0/en unknown
- 2015-07-15 MX MX2019013857A patent/MX2019013857A/es unknown
- 2015-07-16 IL IL239996A patent/IL239996A0/en unknown
-
2019
- 2019-02-08 JP JP2019021752A patent/JP6995069B2/ja not_active Expired - Fee Related
- 2019-08-05 US US16/532,184 patent/US20200199545A1/en not_active Abandoned
-
2020
- 2020-03-13 US US16/818,954 patent/US11702642B2/en active Active
- 2020-06-19 US US16/906,046 patent/US11814654B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016506912A5 (enExample) | ||
| CN106459218B (zh) | 新的重组双功能融合蛋白、其制剂和用途 | |
| JP6723222B2 (ja) | 関節病態の治療 | |
| JP2014526441A5 (enExample) | ||
| HRP20221021T1 (hr) | T stanični receptori specifični za kompleks tumorskog antigena ny-eso-1 sa hla-a*02 | |
| WO2012012600A3 (en) | Peptide compounds for regulating the complement system | |
| IL252631B1 (en) | ACTIVIN-ACTRII antagonists and uses for the treatment of anemia | |
| RU2013139651A (ru) | Новые соединения, влияющие на пищевое поведение | |
| JP2016518351A5 (enExample) | ||
| US12018060B2 (en) | Glucagon derivatives | |
| JP2013533273A5 (enExample) | ||
| AU2015372818A1 (en) | Glucagon derivatives with improved stability | |
| JP2015532293A5 (ja) | 糖尿病患者における心不全の治療用組成物 | |
| JP2014050390A5 (enExample) | ||
| JP2019527053A5 (enExample) | ||
| JP2016506727A5 (enExample) | ||
| JP2009537563A5 (enExample) | ||
| JP2016517421A5 (enExample) | ||
| ES2742179T3 (es) | Composiciones farmacéuticas que comprenden agonistas del receptor de orexina-1 OX1R para el tratamiento de enfermedades inflamatorias del intestino | |
| EP3881856A1 (en) | Pharmaceutical composition for treating aplastic anemia | |
| JP2014530246A5 (enExample) | ||
| JP6615504B2 (ja) | 高血圧症の予防又は治療用医薬 | |
| JP2008531463A5 (enExample) | ||
| JP2009542609A5 (enExample) | ||
| JP5637981B2 (ja) | 関節リウマチまたはその関連疾患の予防または治療剤 |